Here’s our initial take on Novo Nordisk‘s (NYSE: NVO) fiscal 2025 first-quarter financial report. Key Metrics Metric (all figures in Danish kroner) Q1 2024 Q1 2025 Change vs. Expectations Revenue 65.35 billion 78.09 billion 19% Missed Earnings per share 5.68 6.53 15% Beat Operating profit 31.85 billion 38.79 billion 22% n/a Obesity care sales 11.2 … Read more
As the U.S. GLP-1 market is in a period of transition, Novo Nordisk is holding out hope for faster growth in the second half of 2025.
Medications, including some created to treat diabetes, are becoming increasingly popular for their ability to support weight loss. Among these are several drugs that belong to a class known as GLP-1 receptor agonists. While they share similarities, there are differences, particularly in the drugs semaglutide and tirzepatide. Semaglutide, the active ingredient in Ozempic and Wegovy, … Read more
Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs Novo Nordisk shares surged as much as 6.5% in European trading, making it a top performer on the Stoxx 600, as Wall Street analysts said the Danish drugmaker’s guidance cut was largely priced in—and pressures on Wegovy sales from compounded anti-obesity drugs may soon ease. Investor sentiment was … Read more
This text from Fast Company reports on the significant stock price drop experienced by WW International, Inc. (WeightWatchers). The article highlights a report from the Wall Street Journal suggesting the company is contemplating Chapter 11 bankruptcy, which appears to be the primary driver of the stock’s decline. Challenges cited include a large amount of outstanding debt coming due soon, difficulty attracting younger users, the impact of weight-loss medications … Read more
Released: January 7, 2025Level 1 GuidanceDraft This draft guidance document from the U.S. Food and Drug Administration (FDA) outlines recommendations for the development of drugs and biological products intended for weight reduction and maintenance in both adult and pediatric patients with obesity or overweight and related comorbidities. It provides information on clinical trial design, including subject populations, trial size and duration, and the assessment … Read more
WeightWatchers, known for its diet programs once endorsed by celebrities including Oprah Winfrey, has filed for bankruptcy after struggling to compete with weight-loss drugs like Ozempic.
The most expensive drug category for nonfederal hospitals in 2024 were antineoplastic targeted agents, according to a study published in the American Journal of Health-System Pharmacy. The report, published by the American Society of Health-System Pharmacists, found that U.S. drug spending rose 10.2% in 2024 to $805.9 billion, driven largely by the increasing use of … Read more
In a randomized trial, semaglutide had favorable effects on steatohepatitis and fibrosis in liver biopsies.
(MedPage Today) — The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If approved, it would be the first GLP-1 pill indicated for obesity, said maker Novo Nordisk. The rate of…